...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Internet Journal of Asthma, Allergy and Immunology >Role of Eosinophil Cationic Protein in Asthma and Confounding Factors.
【24h】

Role of Eosinophil Cationic Protein in Asthma and Confounding Factors.

机译：嗜酸性粒细胞阳离子蛋白在哮喘和混杂因素中的作用。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: It has been found that activated eosinophils play an important role in the pathogenesis of bronchial asthma.Objective: To clarify the validity of serum Eosinophil Cationic Protein (ECP) as parameter in assessment of asthma since it reflects the pulmonary inflammation in bronchial asthma. Patients and Methods: Serum ECP was determined in 139 asthmatic patients by using enzyme linked immunosorbent assay and compared to control .Results: Serum ECP was very highly significant higher (P<0.00001) in asthmatic patients than in control. There was no overlap between the lower asthmatic limit and higher limit of the control group. In addition, the ECP variation between asthmatic and control was correlated to variations in FEV1 percent predicted (P<0.0001) between both groups. There was an association between serum ECP levels and asthma severity and pattern. A cut – off of 20 μg/l for serum ECP was with sensitivity of 89% and specificity of 88% in detection asthma cases. The area under curve was found to be 0.805, meaning that determination of serum ECP was with a predictive value in detection of asthmatic cases.Conclusion: Serum ECP level may help in discrimination between asthmatic and non asthmatic individuals, also between symptomatic and asymptomatic asthmatic individuals. The residence does not influence serum ECP in our asthmatic patients. Introduction Bronchial asthma is a chronic inflammatory disease of the airway, and the cells mainly responsible for causing this inflammation are eosinophils. When activated eosinophils undergo degranulation causing epithelial damage in the airway, desquamation and increased airway hypersensitivity. Asthma therapy consists of suppressing chronic and persistent airway inflammation. It is, therefore, important to find a marker of disease activity, ideally one that is simple to measure, reliable and inexpensive. As yet no such marker has been found for asthma. A lot of hypotheses have been suggested to propose totally different mechanisms involved in the pathogenesis of asthma. It has been found that activated Eosinophils play an important role in the pathogenesis of bronchial asthma. Upon activation, Eosinophils undergo de-granulation causing epithelial damage in the airway, desquamation and increased airway hypersensitivity. Over the last decades and especially during last ten years substantial research work has been carried out to determine changes in serum ECP levels due to different allergic and non-allergic diseases. As a result enough quality work is now available to bridge the link between Eosinophil activity and allergy phenomenon. Serum ECP is now closer to be declared as an established marker of allergy [1]. Many reported studies demonstrate an increase in serum ECP in asthmatic patients as compared to healthy control [2-9]. Amongst the notable studies of Eosinophil activity markers in induced sputum two studies found that ECP levels were significantly positively correlated with the mean weekly total symptom scores [10,11]. The review of literature indicated that serum ECP may serve as objective indicator for clinical activity in the asthma, and point to a possible pathophysiological axis in asthma that is based upon altered airway resistance due to Eosinophils and Eosinophil activity markers [2,12,13]. If it is confirmed that this axis has some role in pathophysiology of asthma then it will open doors to new pharmaceutical research targeted at developing anti-eosinophil activity drugs on the pattern of anti histamine drugs [14]. The studies that mentioned above will eventually establish the importance of serum ECP in diagnosis and management of asthma. Interleukin -5 (IL-5) , a cytokine that attracts, activates and prolongs survival of eosinophils, is an important eosinophil- regulating cytokines in the pathogenesis of allergic inflammation and asthma, and its concentration in asthmatics correlates with markers of Eosinophil activation and T Lymphocyte [15]. IL-5 was detecta
机译：背景：已发现活化的嗜酸性粒细胞在支气管哮喘的发病过程中起着重要的作用。目的：阐明血清嗜酸性粒细胞阳离子蛋白（ECP）作为哮喘评估参数的有效性，因为它反映了支气管哮喘的肺部炎症。患者与方法：采用酶联免疫吸附法测定了139例哮喘患者的血清ECP，并与对照组进行了比较。结果：哮喘患者的血清ECP显着高于对照组（P <0.00001）。哮喘的下限与对照组的上限之间没有重叠。此外，哮喘和对照之间的ECP变化与两组之间预测的FEV1％的变化相关（P <0.0001）。血清ECP水平与哮喘严重程度和类型之间存在关联。在检测出的哮喘病例中，血清ECP的临界值是20μg/ l，敏感性为89％，特异性为88％。发现曲线下的面积为0.805，这意味着确定血清ECP对检测哮喘病例具有预测价值。结论：血清ECP水平可能有助于区分哮喘和非哮喘患者，以及有症状和无症状的哮喘患者。该住所不影响我们哮喘患者的血清ECP。引言支气管哮喘是气道的一种慢性炎症性疾病，引起这种炎症的主要细胞是嗜酸性粒细胞。当活化的嗜酸性粒细胞脱颗粒而导致气道上皮损伤，脱屑并增加气道超敏性时。哮喘治疗包括抑制慢性和持续性气道炎症。因此，重要的是找到疾病活动的标记，理想地，该标记易于测量，可靠且廉价。迄今为止，尚未发现哮喘的这种标记。已经提出了许多假说来提出与哮喘发病机理完全不同的机制。已经发现活化的嗜酸性粒细胞在支气管哮喘的发病机理中起重要作用。活化后，嗜酸性粒细胞发生去颗粒化，导致气道上皮受损，脱屑并增加气道超敏性。在过去的几十年中，尤其是在过去的十年中，已经进行了大量的研究工作来确定由于不同的过敏性疾病和非过敏性疾病引起的血清ECP水平的变化。结果，现在可以进行足够的高质量工作来弥合嗜酸性粒细胞活性与过敏现象之间的联系。血清ECP现在更接近被宣布为过敏的既定标志物[1]。许多报道的研究表明，与健康对照组相比，哮喘患者的血清ECP升高[2-9]。在诱导痰中嗜酸性粒细胞活性标志物的著名研究中，两项研究发现ECP水平与每周平均总症状评分显着正相关[10,11]。文献综述表明，血清ECP可能是哮喘临床活动的客观指标，并指出哮喘的可能病理生理轴是基于嗜酸性粒细胞和嗜酸性粒细胞活性标记物引起的气道阻力改变[2,12,13] 。如果证实该轴在哮喘的病理生理中起一定作用，那么它将为以抗组胺药的模式开发抗嗜酸性粒细胞活性药物为目标的新药物研究打开大门[14]。上述研究最终将确定血清ECP在哮喘的诊断和管理中的重要性。白细胞介素-5（IL-5）是一种吸引，激活和延长嗜酸性粒细胞存活的细胞因子，是变应性炎症和哮喘发病机理中重要的嗜酸性粒细胞调节细胞因子，其在哮喘患者中的浓度与嗜酸性粒细胞活化和T的标志物相关淋巴细胞[15]。 IL-5被检出

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号